Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Accounts Payables: 2009-2025

Historic Accounts Payables for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $556,000.

  • Gyre Therapeutics' Accounts Payables rose 83.50% to $556,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $556,000, marking a year-over-year increase of 83.50%. This contributed to the annual value of $108,000 for FY2024, which is 69.58% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Accounts Payables of $556,000 as of Q3 2025, which was up 683.10% from $71,000 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Accounts Payables registered a high of $6.4 million during Q4 2021, and its lowest value of $5,000 during Q2 2023.
  • Moreover, its 3-year median value for Accounts Payables was $158,000 (2023), whereas its average is $208,636.
  • In the last 5 years, Gyre Therapeutics' Accounts Payables crashed by 99.66% in 2023 and then spiked by 5,320.00% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Accounts Payables (Quarterly) stood at $6.4 million in 2021, then crashed by 98.10% to $122,000 in 2022, then surged by 190.98% to $355,000 in 2023, then plummeted by 69.58% to $108,000 in 2024, then surged by 83.50% to $556,000 in 2025.
  • Its Accounts Payables was $556,000 in Q3 2025, compared to $71,000 in Q2 2025 and $122,000 in Q1 2025.